Relationship between the Serotonergic Activity and Rei Amphetamine Analogs

Journal of Pharmacology and Experimental Therapeutics 313, 848-854 DOI: 10.1124/jpet.104.080101

Citation Report

#	Article	IF	CITATIONS
1	Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1361-1369.	2.5	83
2	Role of the increased noradrenergic neurotransmission in drug self-administration. Drug and Alcohol Dependence, 2006, 82, 151-157.	3.2	23
3	Therapeutic Potential of Monoamine Transporter Substrates. Current Topics in Medicinal Chemistry, 2006, 6, 1845-1859.	2.1	53
4	Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine. Trends in Pharmacological Sciences, 2006, 27, 105-112.	8.7	67
5	Dual dopamine–5-HT releasers: potential treatment agents for cocaine addiction. Trends in Pharmacological Sciences, 2006, 27, 612-618.	8.7	39
6	Pharmacological determinants of the reinforcing effects of psychostimulants: Relation to agonist substitution treatment Experimental and Clinical Psychopharmacology, 2006, 14, 20-33.	1.8	39
7	Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine-Type Drugs. Annals of the New York Academy of Sciences, 2006, 1074, 245-260.	3.8	108
8	Estimating the relative reinforcing strength of (±)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology, 2006, 189, 483-488.	3.1	53
9	Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys. Pharmacology Biochemistry and Behavior, 2006, 84, 337-343.	2.9	47
10	Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration. Pharmacology Biochemistry and Behavior, 2006, 85, 454-463.	2.9	24
11	Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 757-765.	2.5	69
12	Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate "Agonist―Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys. Journal of Pharmacology and	2.5	70
14	Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors. Progress in Neurobiology, 2007, 81, 133-178.	5.7	297
15	The effects of concurrent administration of (±)3,4-Methylenedioxymethamphetamine and cocaine on conditioned place preference in the adult male rat. Pharmacology Biochemistry and Behavior, 2007, 88, 165-170.	2.9	19
16	Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions. AAPS Journal, 2007, 9, E1-E10.	4.4	55
17	MDMA selfâ€administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. European Journal of Neuroscience, 2007, 26, 3229-3236.	2.6	75
18	Serotonin (5â€HT) Transporter Ligands Affect Plasma 5â€HT in Rats. Annals of the New York Academy of Sciences, 2008, 1139, 268-284.	3.8	20
19	Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology, 2008, 75, 196-217.	4.4	189

#	ARTICLE	IF	CITATIONS
20	Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacology Biochemistry and Behavior, 2008, 90, 453-462.	2.9	42
21	Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction Experimental and Clinical Psychopharmacology, 2008, 16, 458-474.	1.8	57
22	Pharmacology of stimulants prohibited by the World Antiâ€Đoping Agency (WADA). British Journal of Pharmacology, 2008, 154, 606-622.	5.4	97
23	Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (<i>1S</i> , <i>2S</i>)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 573-583.	2.5	47
24	Dopamine/serotonin releasers as medications for stimulant addictions. Progress in Brain Research, 2008, 172, 385-406.	1.4	38
26	Nonhuman primate neuroimaging and cocaine medication development Experimental and Clinical Psychopharmacology, 2008, 16, 446-457.	1.8	10
27	MDMA Self-Administration in Laboratory Animals: A Summary of the Literature and Proposal for Future Research. Neuropsychobiology, 2009, 60, 130-136.	1.9	47
28	Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 272-281.	2.5	34
29	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 236-248.	2.5	14
30	Lack of Cocaine Self-Administration in Mice Expressing a Cocaine-Insensitive Dopamine Transporter. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 204-211.	2.5	90
31	Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacology Biochemistry and Behavior, 2009, 94, 278-284.	2.9	18
32	Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug and Alcohol Dependence, 2009, 100, 234-239.	3.2	30
34	Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology, 2010, 210, 75-83.	3.1	15
35	In Vivo Effects of Amphetamine Analogs Reveal Evidence for Serotonergic Inhibition of Mesolimbic Dopamine Transmission in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 218-225.	2.5	95
36	Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats. Life Sciences, 2011, 88, 586-589.	4.3	7
37	Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. Behavioural Pharmacology, 2011, 22, 824-836.	1.7	41
39	Dopaminergic mechanisms of reinstatement of MDMAâ€seeking behaviour in rats. British Journal of Pharmacology, 2011, 162, 1770-1780.	5.4	39
40	MDMA ("ecstasyâ€) abuse as an example of dopamine neuroplasticity. Neuroscience and Biobehavioral Reviews, 2011, 35, 1203-1218.	6.1	33

#	Article	IF	CITATIONS
41	Agonist replacement therapy for cocaine dependence: a translational review. Future Medicinal Chemistry, 2012, 4, 245-265.	2.3	44
42	Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain Research, 2012, 1470, 119-129.	2.2	10
43	GC–MS and GC–IRD analysis of 2-, 3- and 4-methylmethamphetamine and 2-, 3- and 4-methylamphetamine. Forensic Science International, 2012, 220, 67-73.	2.2	18
44	Fluorine in psychedelic phenethylamines. Drug Testing and Analysis, 2012, 4, 577-590.	2.6	28
45	Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology, 2012, 220, 751-762.	3.1	79
46	Isomers of fluoroamphetamines detected in forensic cases in Denmark. International Journal of Legal Medicine, 2012, 126, 541-547.	2.2	35
47	Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. Forensic Science International, 2012, 215, 3-7.	2.2	24
48	Synthetic Amphetamine Derivatives. , 2013, , 161-178.		6
49	Computerâ€aided (<i>in silico</i>) approaches in the modeâ€ofâ€action analysis and safety assessment of Ostarine and 4â€methylamphetamine. Human Psychopharmacology, 2013, 28, 365-378.	1.5	2
50	Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive â€ [~] Bath Salts' Products. Neuropsychopharmacology, 2013, 38, 552-562.	5.4	361
51	Pharmacological characterization of designer cathinones <i>in vitro</i> . British Journal of Pharmacology, 2013, 168, 458-470.	5.4	576
52	Use of intracranial selfâ€stimulation to evaluate abuseâ€related and abuseâ€limiting effects of monoamine releasers in rats. British Journal of Pharmacology, 2013, 168, 850-862.	5.4	102
53	The identification of 4-methylamphetamine and its synthesis by-products in forensic samples. Forensic Science International, 2013, 228, 115-131.	2.2	14
54	Differentiation of regioisomeric fluoroamphetamine analogs by gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry. Forensic Toxicology, 2013, 31, 241-250.	2.4	32
55	4-Methyl-amphetamine: a health threat for recreational amphetamine users. Journal of Psychopharmacology, 2013, 27, 817-822.	4.0	34
56	Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. International Journal of Neuropsychopharmacology, 2013, 16, 1985-1998.	2.1	15
57	Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats. Behavioural Pharmacology, 2013, 24, 448-458.	1.7	13
58	Abuse liability of novel â€~legal high' designer stimulants. Behavioural Pharmacology, 2013, 24, 341-355.	1.7	16

#	Article	IF	CITATIONS
59	Differentiation of regioisomeric methylamphetamines by GC/MS. Japanese Journal of Forensic Science and Technology, 2014, 19, 111-119.	0.1	5
60	Bath Salts, Mephedrone, and Methylenedioxypyrovalerone as Emerging Illicit Drugs That Will Need Targeted Therapeutic Intervention. Advances in Pharmacology, 2014, 69, 581-620.	2.0	64
61	Monoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse. Advances in Pharmacology, 2014, 69, 129-176.	2.0	50
62	Emerging drugs of abuse: current perspectives on substituted cathinones. Substance Abuse and Rehabilitation, 2014, 5, 37.	4.8	63
63	Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MS n. Analytical and Bioanalytical Chemistry, 2014, 406, 1957-1974.	3.7	30
64	Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochemical Pharmacology, 2014, 88, 237-244.	4.4	85
65	Synthetic Cathinones ("Bath Saltsâ€) . Journal of Emergency Medicine, 2014, 46, 632-642.	0.7	131
66	Pharmacology of novel synthetic stimulants structurally related to the "bath salts―constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology, 2014, 87, 206-213.	4.1	176
67	Predicting abuse potential of stimulants and other dopaminergic drugs: Overview and recommendations. Neuropharmacology, 2014, 87, 66-80.	4.1	28
68	Acquisition of <scp>MDMA</scp> selfâ€administration: pharmacokinetic factors and <scp>MDMA</scp> â€induced serotonin release. Addiction Biology, 2014, 19, 874-884.	2.6	45
69	Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology, 2014, 79, 152-160.	4.1	176
70	Intracranial Self-Stimulation to Evaluate Abuse Potential of Drugs. Pharmacological Reviews, 2014, 66, 869-917.	16.0	185
71	Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys Experimental and Clinical Psychopharmacology, 2014, 22, 274-284.	1.8	16
72	Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA (†Ecstasy') Substance Use Disorder. Current Topics in Behavioral Neurosciences, 2015, 34, 17-32.	1.7	2
74	New Synthetic Drugs in Addictovigilance. Therapie, 2015, 70, 179-189.	1.0	10
75	Do the risks of khat-induced dependence and psychosis warrant the 2014 UK ban?. Drug Science, Policy and Law, 2015, 2, 205032451662844.	1.3	1
76	4â€Fluoroamphetamine in the Netherlands: more than a oneâ€night stand. Addiction, 2015, 110, 1138-1143.	3.3	42
77	Serotonin 5-HT ₂ Receptor Interactions with Dopamine Function: Implications for Therapeutics in Cocaine Use Disorder. Pharmacological Reviews, 2015, 67, 176-197.	16.0	214

#	Article	IF	CITATIONS
78	Serotonin is involved in the psychostimulant and hypothermic effect of 4-methylamphetamine in rats. Neuroscience Letters, 2015, 590, 68-73.	2.1	5
79	Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. European Neuropsychopharmacology, 2015, 25, 365-376.	0.7	162
80	Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug and Alcohol Dependence, 2015, 147, 1-19.	3.2	116
81	Effects of Â-Pyrrolidinopentiophenone and 4-Methyl-N-Ethylcathinone, Two Synthetic Cathinones Commonly Found in Second-Generation "Bath Salts," on Intracranial Self-Stimulation Thresholds in Rats. International Journal of Neuropsychopharmacology, 2015, 18, pyu014-pyu014.	2.1	30
82	Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain, 2015, 156, 175-184.	4.2	30
83	In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology, 2015, 232, 3045-3055.	3.1	92
84	Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Medical Weekly, 2015, 145, w14043.	1.6	136
85	Persistent sensitisation to the locomotor activating effects of MDMA following MDMA self-administration in rats. Pharmacology Biochemistry and Behavior, 2015, 132, 103-107.	2.9	9
86	Pharmacological profile of novel psychoactive benzofurans. British Journal of Pharmacology, 2015, 172, 3412-3425.	5.4	91
87	Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology, 2015, 92, 90-97.	4.1	81
88	4,4′â€ <scp>DMAR</scp> : Chemistry, Pharmacology and Toxicology of a New Synthetic Stimulant of Abuse. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 26-30.	2.5	6
89	Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Drug and Alcohol Dependence, 2015, 157, 18-27.	3.2	42
90	Role of 5-HT2C receptors in effects of monoamine releasers on intracranial self-stimulation in rats. Psychopharmacology, 2015, 232, 3249-3258.	3.1	9
91	Intravenous self-administration of entactogen-class stimulants inÂmale rats. Neuropharmacology, 2015, 99, 538-545.	4.1	56
92	New Psychoactive Substances. Therapeutic Drug Monitoring, 2016, 38, 4-11.	2.0	56
93	Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration. Current Topics in Behavioral Neurosciences, 2016, 32, 145-164.	1.7	30
94	The Effects of 4-Methylethcathinone on Conditioned Place Preference, Locomotor Sensitization, and Anxiety-Like Behavior: A Comparison with Methamphetamine. International Journal of	2.1	28
	Neuropsychophannacology, 2010, 19, pyv120.		

#	Article	IF	CITATIONS
96	Reinforcing Effects of Cathinone NPS in the Intravenous Drug Self-Administration Paradigm. Current Topics in Behavioral Neurosciences, 2016, 32, 133-143.	1.7	26
98	Interactions of Cathinone NPS with Human Transporters and Receptors in Transfected Cells. Current Topics in Behavioral Neurosciences, 2016, 32, 49-72.	1.7	21
99	4-Fluoroamphetamine in Serum and Urine from an Intoxicated Patient with Life-Threatening Hyperpyrexia: TableÂl Journal of Analytical Toxicology, 2016, 40, 171-172.	2.8	11
100	Repeated administration of the 5-HT1B/1A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT1A and 5-HT1B receptor mechanisms. Psychopharmacology, 2016, 233, 1339-1347.	3.1	8
101	Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. European Neuropsychopharmacology, 2016, 26, 288-297.	0.7	20
102	The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue. Neuropharmacology, 2016, 101, 68-75.	4.1	20
103	Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys. Addiction Biology, 2017, 22, 1169-1178.	2.6	29
104	Separation of ortho, meta and para isomers of methylmethcathinone (MMC) and methylethcathinone (MEC) using LC-ESI-MS/MS: Application to forensic serum samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1051, 118-125.	2.3	21
105	Repeated MDMA administration increases MDMA-produced locomotor activity and facilitates the acquisition of MDMA self-administration: role of dopamine D2 receptor mechanisms Psychopharmacology, 2017, 234, 1155-1164.	3.1	14
106	Blockade of the 5â€HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine. British Journal of Pharmacology, 2017, 174, 2716-2738.	5.4	28
107	N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability. Neuropsychopharmacology, 2017, 42, 1950-1961.	5.4	26
108	Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) In Self-Administering Rats. ACS Chemical Neuroscience, 2017, 8, 2648-2654.	3.5	17
109	Cocaine-like discriminative stimulus effects of "norepinephrine-preferring―monoamine releasers: time course and interaction studies in rhesus monkeys. Psychopharmacology, 2017, 234, 3455-3465.	3.1	8
110	Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine. Drug and Alcohol Dependence, 2017, 180, 39-45.	3.2	18
111	Non-medical and illicit use of psychoactive drugs. Current Topics in Behavioral Neurosciences, 2017, , .	1.7	2
112	The serotonin 5-HT _{2C} receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 2017, 31, 127-143.	4.0	43
113	Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 33-47.	2.5	110
114	Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacology Biochemistry and Behavior, 2017, 152, 52-60.	2.9	13

ARTICLE IF CITATIONS # An Update on the Role of Serotonin and its Interplay with Dopamine for Reward. Frontiers in Human 2.0 102 115 Neuroscience, 2017, 11, 484. Monoamine Transporter and Receptor Interaction Profiles of Synthetic Cathinones. Current Topics in 0.4 Neurotoxicity, 2018, , 97-115. 117 Synthetic Cathinones. Current Topics in Neurotoxicity, 2018, , . 0.4 4 Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances. Handbook of 118 1.8 Experimental Pharmacology, 2018, 252, 143-164. "Ecstasy―to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of 119 4.1 31 MDMA. Neuropharmacology, 2018, 133, 171-180. Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in 5.4 rats. Neuropsychopharmacology, 2018, 43, 1753-1762. Effects of <i>N</i>-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine 121 3.5 10 Transporters and Abuse-Related Behavior. ACS Chemical Neuroscience, 2018, 9, 1829-1839. Pharmacological profile of mephedrone analogs and related new psychoactive substances. 4.1 Neuropharmacology, 2018, 134, 4-12. Reinforcing Effects of Binary Mixtures of Common Bath Salt Constituents: Studies with 123 3,4-Methylenedioxypyrovalerone (MDPV), 3,4-Methylenedioxymethcathinone (methylone), and Caffeine 5.4 37 in Rats. Neuropsychopharmacology, 2018, 43, 761-769. Neuropharmacology of Synthetic Cathinones. Handbook of Experimental Pharmacology, 2018, 252, 124 1.8 113-142. New psychoactive substancesâ€"Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science, 125 12 2.1 2019, Í, . Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats. 3.1 Psychopharmacology, 2018, 235, 3233-3241. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and 127 5.4 64 selectivity to inhibit the dopamine transporter. Neuropsychopharmacology, 2018, 43, 2399-2407. The Prevention and Treatment of Adolescent Stimulant and Methamphetamine Use. Issues in Children's 0.2 and Families' Lives, 2018, , 233-260. Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics. International Journal of Neuropsychopharmacology, 130 2.1 63 2018, 21, 926-931. Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine. 3.1 Psychopharmacology, 2018, 235, 2349-2356. Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) 132 3.514 Administration in Humans. Frontiers in Pharmacology, 2018, 9, 713. Systematic Investigation into the Differences in the (+) APPI Efficiencies of Positional (Ortho, Meta,) Tj ETQq1 1 0.784314 rgBT /Over

#	Article	IF	CITATIONS
134	Medications development for food-based and drug use disorders. Advances in Pharmacology, 2019, 86, 197-236.	2.0	1
135	Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones. Frontiers in Pharmacology, 2019, 10, 438.	3.5	24
136	The synthetic cathinone psychostimulant αâ€PPP antagonizes serotonin 5â€HT _{2A} receptors: In vitro and in vivo evidence. Drug Testing and Analysis, 2019, 11, 990-998.	2.6	8
137	The SERT Met172 Mouse: An Engineered Model To Elucidate the Contributions of Serotonin Signaling to Cocaine Action. ACS Chemical Neuroscience, 2019, 10, 3053-3060.	3.5	8
138	2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors. Psychopharmacology, 2019, 236, 989-999.	3.1	3
139	Pharmacological characterization of the aminorex analogs 4-MAR, 4,4′-DMAR, and 3,4-DMAR. NeuroToxicology, 2019, 72, 95-100.	3.0	11
140	Effects of cocaine on the discriminative stimulus and reinforcing effects of mephedrone in male rats. Psychopharmacology, 2019, 236, 1043-1056.	3.1	2
141	The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes. Psychopharmacology, 2019, 236, 915-924.	3.1	12
142	Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology, 2019, 236, 939-952.	3.1	42
143	Behavioral economic analysis of the reinforcing effects of "bath salts―mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats. Psychopharmacology, 2019, 236, 1031-1041.	3.1	16
144	The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. Drug Delivery and Translational Research, 2020, 10, 271-281.	5.8	3
145	The potent psychomotor, rewarding and reinforcing properties of 3â€fluoromethamphetamine in rodents. Addiction Biology, 2020, 25, e12846.	2.6	7
146	Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters. Frontiers in Pharmacology, 2020, 11, 673.	3.5	13
147	Transdermal Delivery of the Free Base of 3-Fluoroamphetamine: In Vitro Skin Permeation and Irritation Potential. AAPS PharmSciTech, 2020, 21, 109.	3.3	3
148	Construction of pioneering quantitative structure activity relationship screening models for abuse potential of designer drugs using index of ideality of correlation in monte carlo optimization. Archives of Toxicology, 2020, 94, 3069-3086.	4.2	22
149	The synthetic cathinone 3,4-methylenedioxypyrovalerone increases impulsive action in rats. Behavioural Pharmacology, 2020, 31, 309-321.	1.7	3
150	Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats. Psychopharmacology, 2020, 237, 1681-1689.	3.1	3
151	Designer drugs: mechanism of action and adverse effects. Archives of Toxicology, 2020, 94, 1085-1133.	4.2	138

#	Article	IF	CITATIONS
152	Convenient ultrasonic preparation of a water stable cluster-based Cadmium(II) coordination material and highly sensitive fluorescent sensing for biomarkers DPA and 5-HT. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 247, 119092.	3.9	7
153	Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. Journal of Psychopharmacology, 2021, 35, 512-536.	4.0	22
154	Drugs of Abuse Affecting 5-HT2B Receptors. Receptors, 2021, , 277-289.	0.2	3
155	The Reward System and Post-Traumatic Stress Disorder: Does Trauma Affect the Way We Interact With Positive Stimuli?. Chronic Stress, 2021, 5, 247054702199600.	3.4	30
156	Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses. Pharmacology Biochemistry and Behavior, 2021, 202, 173112.	2.9	13
157	Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse. Journal of Neurochemistry, 2021, 157, 1714-1724.	3.9	18
158	Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity in vitro. Frontiers in Pharmacology, 2021, 12, 654061.	3.5	9
159	Discriminative-Stimulus Effects of Synthetic Cathinones in Squirrel Monkeys. International Journal of Neuropsychopharmacology, 2021, 24, 656-665.	2.1	3
160	Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. Life, 2021, 11, 440.	2.4	11
161	Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca2+ channels as sensors. Toxicology and Applied Pharmacology, 2021, 419, 115513.	2.8	6
162	α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter. Neuropharmacology, 2021, 190, 108570.	4.1	15
163	Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Experimental Neurology, 2021, 343, 113778.	4.1	30
164	Pharmacological profiling of novel psychoactive substances. , 2022, , 109-130.		0
165	Synthetic amphetamine derivatives, benzofurans, and benzodifurans. , 2022, , 247-278.		1
166	Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions. , 2008, , 311.		3
167	Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology, 2020, 237, 1471-1480.	3.1	34
168	Methaemoglobinaemia due to mephedrone ('snow'). BMJ Case Reports, 2010, 2010, bcr0420102879-bcr0420102879.	0.5	11
169	The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts― Journal of Addiction Research & Therapy, 2013, 04, .	0.2	52

		Citation Report		
#	Article		IF	Citations
170	Profile of MDMA Self-Administration from a Large Cohort of Rats: MDMA Develops a P Dependence with Extended Testing. Journal of Drug and Alcohol Research, 2012, 1, 1-6	rofile of 5.	0.9	19
171	(2-Aminopropyl)benzo[l²]thiophenes (APBTs) are novel monoamine transporter ligand stimulant effects but display psychedelic-like activity in mice. Neuropsychopharmacolc 914-923.	s that lack gy, 2022, 47,	5.4	8
173	The role of extracellular serotonin and MDMA in the sensitizing effects of MDMA. Beha Research, 2022, 430, 113936.	ivioural Brain	2.2	1
175	4â€Fluoroamphetamine (4â€FA) intoxication results in exaggerated blood pressure eff MDMA and amphetamine: A retrospective analysis. Journal of the American College of Physicians Open, 2022, 3, .	ects compared to Emergency	0.7	0
176	Serotonin-releasing agents with reduced off-target effects. Molecular Psychiatry, 2023	, 28, 722-732.	7.9	10
177	Persistent binding at dopamine transporters determines sustained psychostimulant ef Proceedings of the National Academy of Sciences of the United States of America, 202	fects. 23, 120, .	7.1	5
178	Rate of onset of dopamine transporter inhibitors assessed with intracranial self-stimula vivo dopamine photometry in rats. Psychopharmacology, 2023, 240, 969-981.	ition and in	3.1	1
179	Characterization of neurotransmitter inhibition for seven cathinones by a proprietary f dye method. Drug Testing and Analysis, 0, , .	luorescent	2.6	4
180	Mephedrone induces partial release at human dopamine transporters but full release a serotonin transporters. Neuropharmacology, 2023, 240, 109704.	t human	4.1	0
181	α-Pyrrolidinohexanophenone (α-PHP) vs. α-pyrrolidinoisohexanophenone (α-PiHP): A investigation about plasma concentrations and behavior in forensic routine cases. Jour Analytical Toxicology, 0, , .	toxicological nal of	2.8	0
182	Effects of the designer drug 4-methylamphetamine on core temperature and serotonir striatum and hippocampus of rats. Neuroscience Letters, 2024, 827, 137740.	levels in the	2.1	0